Corrigendum: Epigenetic immune monitoring for COVID-19 disease course prognosis

Affiliations

¹ Ivana Türbachova Laboratory for Epigenetics, Epiontis, Precision for Medicine GmbH, Berlin, Germany.
² Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
³ Department of Anesthesiology and Resuscitation, Consortium General University Hospital of Valencia, Valencia, Spain.
⁴ Center for Translational Medicine, Medical Clinic 1, Marien Hospital Herne, University Hospitals of the Ruhr-University of Bochum, Herne, Germany.

Published Erratum

Björn Samans et al. Front Immunol. 2024.

. 2024 Jun 27:15:1451571.

doi: 10.3389/fimmu.2024.1451571. eCollection 2024.

¹ Ivana Türbachova Laboratory for Epigenetics, Epiontis, Precision for Medicine GmbH, Berlin, Germany.
² Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
³ Department of Anesthesiology and Resuscitation, Consortium General University Hospital of Valencia, Valencia, Spain.
⁴ Center for Translational Medicine, Medical Clinic 1, Marien Hospital Herne, University Hospitals of the Ruhr-University of Bochum, Herne, Germany.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1107900.].

Keywords: COVID-19; SARS-CoV-2; disease prognosis; epigenetic qPCR; immune monitoring; lymphopenia.

Epigenetic immune monitoring for COVID-19 disease course prognosis.
Samans B, Rosselló Chornet M, Rosselló Chornet A, Jung J, Schildknecht K, Lozza L, Alos Zaragoza L, Hernández Laforet J, Babel N, Olek S. Samans B, et al. Front Immunol. 2023 Mar 14;14:1107900. doi: 10.3389/fimmu.2023.1107900. eCollection 2023. Front Immunol. 2023. PMID: 36999021 Free PMC article.